Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
NCT06626919 · View on ClinicalTrials.gov ↗
Study Summary
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
Conditions Studied
Interventions
- BIOLOGICAL anito-cel
- DRUG Standard Lymphodepletion regimen
Study Locations (13)
California
- UCLA Medical Center — Los Angeles
- University of California, Irvine — Orange
- Stanford Hospital — Palo Alto
Minnesota
- University of Minnesota Delaware Clinical Research Unit — Minneapolis
- Mayo Clinic — Rochester
Texas
- UT Southwestern Medical Center — Dallas
- Houston Methodist Hospital — Houston
Florida
- University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare — Tampa
Michigan
- Karmanos Cancer Institute — Detroit
New York
- Columbia University Irving Medical Center — New York
Ohio
- Ohio State University — Columbus
Oregon
- Oregon Health & Science University (OHSU) — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-04-30 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06626919
The ClinicalTrials.gov registry entry for NCT06626919 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcellx, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions — of which anito-cel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06626919 reports 13 study locations spanning 9 distinct geographic areas — top geographies include California, Minnesota, Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06626919 about?
NCT06626919 is a clinical study titled "A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases". A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
What is the current status of trial NCT06626919?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-04-30. Estimated completion is 2028-04.
What conditions does trial NCT06626919 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Autoimmune Diseases, Muscle Weakness, Neuromuscular Manifestations, Muscular Diseases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06626919?
The interventions under investigation include: anito-cel (BIOLOGICAL), Standard Lymphodepletion regimen (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06626919?
This trial is sponsored by Arcellx, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06626919 being conducted?
This trial has 13 study locations across California, Florida, Michigan, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.